Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Non-Current Debt across 18 years of filings, most recently posting $14.0 billion for Q1 2026.

• Quarterly Non-Current Debt fell 13.65% year-over-year to $14.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 billion (down 13.65% YoY) and the FY2025 annual result came in at $15.0 billion, down 6.35% from the prior year.
• Non-Current Debt fell to $14.0 billion in Q1 2026, from $15.0 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $20.8 billion in Q1 2022 and troughed at $14.0 billion in Q1 2026.
• A 5-year average of $17.5 billion and a median of $16.8 billion in 2025 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt retreated 15.68% — and 2025, when it advanced 2.23%.
• Tracing TEVA's Non-Current Debt over 5 years: stood at $19.1 billion in 2022, then declined by 4.93% to $18.2 billion in 2023, then retreated by 11.89% to $16.0 billion in 2024, then dropped by 6.35% to $15.0 billion in 2025, then declined by 6.48% to $14.0 billion in 2026.
• Business Quant data shows TEVA's Non-Current Debt at $14.0 billion in Q1 2026, $15.0 billion in Q4 2025, and $16.8 billion in Q3 2025.